Pfizer Corporate
Description
Vocal Characteristics
Language
EnglishVoice Age
Young Adult (18-35)Accents
British (General) Trans-AtlanticTranscript
Note: Transcripts are generated using speech recognition software and may contain errors.
in lighter the new face of second line MRCC treatment. On the occasion of the launch of In Lighter FIZA Oncology, Austria invited key opinion leaders across the country to discuss data and share experiences after Sutent. The gold standard in first line MRCC treatment is in lighter substance accident ib ah highly potent therapy and second line treatment. This highly effective and selective drug is probably one of the strongest inhibitors of V g. Fr currently available on the market. In October, 2012 in lighter was included in the guidelines of the European Society for Medical Oncology with the highest level of evidence in second line treatment for advanced renal cell carcinoma. The goal of the launch events was to bring the important MRCC prescribers up to date as soon as possible and present the impressive data. Andrea Life Experiences This road show was chaired by local key opinion leaders on Manuela Schmidinger, top expert in the field of MRCC. As you can see, it was a big success